Seed radiation plus fluzoparib for advanced soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether combining seed radiation (iodine-125 placed in/near the tumor) with fluzoparib can better control advanced, hard-to-remove soft tissue sarcoma. It may help shrink tumors and slow progression, but you must meet several cancer, health, and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (age 18 or older) and sign consent to join.
- You have confirmed soft tissue sarcoma that can be measured on CT or MRI, with 1 small-enough target area (no more than 5 total spots).
- Your cancer has already had standard first treatment (like doxorubicin + ifosfamide) and possibly surgery, but can’t be fully removed.
- You can swallow pills normally, and your general health is fairly strong (ECOG 0 to 1) with expected survival of at least 12 weeks.
- Your blood counts and organ tests (kidneys, liver, thyroid, etc.) must be within limits for safe treatment.
- If you can become pregnant or impregnate someone: you must use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This Phase 2 trial tests whether giving radiation before surgery, along with anlotinib and penpulimab, can improve treatment for localized soft tissue sarcoma. It may help shrink or control the tumor before conservative surgery.
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
This trial tests a new combination of radiation therapy and an immunotherapy approach (called PraG) for people with advanced soft tissue sarcoma that can't be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
Hear when a new Brachytherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.